Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DWIGHT DENMAN BLAKE

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1811938814
CMS profile
173473
Location
UNION CITY, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$369.25

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $369.25 3

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $369.25 3

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DWIGHT DENMAN BLAKE

NPI 1811938814 · CMS profile ID 173473

Allopathic & Osteopathic Physicians / Internal Medicine

UNION CITY, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1811938814?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DWIGHT DENMAN BLAKE, NPI 1811938814, CMS profile ID 173473. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1811938814?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). DWIGHT DENMAN BLAKE, NPI 1811938814, CMS profile ID 173473. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1811938814?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
DWIGHT DENMAN BLAKE, NPI 1811938814, CMS profile ID 173473, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1811938814?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $369.25 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $122.4609/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206226406 CMS
AstraZeneca Pharmaceuticals LP $123.6708/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206781539 CMS
AstraZeneca Pharmaceuticals LP $123.1203/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206548933 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,138.93 6
PY2020 $1,159.49 24
PY2021 $122.45 1
PY2022 $473.01 5
PY2024 $1,818.96 5
PY2025 $369.25 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,386,564.75 80
PY2024 Recipient $57,732.20 4
PY2024 Principal investigator $2,455,115.26 49
PY2023 Recipient $2,277.99 4
PY2023 Principal investigator $2,791,306.83 51
PY2022 Recipient $92,276.00 3
PY2022 Principal investigator $3,022,384.19 43
PY2021 Recipient $6,646.99 2
PY2021 Principal investigator $1,337,039.14 22
PY2020 Recipient $1,658.45 3
PY2020 Principal investigator $145,341.90 6
PY2019 Recipient $24,425.96 3
PY2019 Principal investigator $177,128.41 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

46 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $244.61 12/31/2022 Non-covered Recipient Entity
CENTRO DE INVESTIGACIONES CLINICAS
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 965539843
Principal investigator 1 ABBVIE INC. $970.61 12/31/2022 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 965539845
Principal investigator 1 PFIZER INC. $70,928.20 12/17/2022 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949769373
Principal investigator 1 PFIZER INC. $53,807.60 12/16/2022 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949769581
Principal investigator 1 PFIZER INC. $107,615.20 12/10/2022 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949769371
Principal investigator 1 PFIZER INC. $22,435.86 12/08/2022 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 949770485
Principal investigator 1 PFIZER INC. $55.89 12/05/2022 Non-covered Recipient Entity
Rophe Adult and Ped Medicine
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949763469
Principal investigator 1 PFIZER INC. $12,229.00 12/03/2022 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949769369
Principal investigator 1 PFIZER INC. $12,229.00 11/23/2022 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949780351
Principal investigator 1 PFIZER INC. $74.52 11/21/2022 Non-covered Recipient Entity
Rophe Adult and Ped Medicine
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949763471
Principal investigator 1 PFIZER INC. $53,807.60 11/10/2022 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949780577
Principal investigator 1 PFIZER INC. $14,325.00 11/09/2022 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949780579
Principal investigator 1 PFIZER INC. $18.63 10/24/2022 Non-covered Recipient Entity
Rophe Adult and Ped Medicine
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949763403
Principal investigator 1 PFIZER INC. $18.63 10/24/2022 Non-covered Recipient Entity
Rophe Adult and Ped Medicine
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949763405
Principal investigator 1 PFIZER INC. $55.89 10/18/2022 Non-covered Recipient Entity
Rophe Adult and Ped Medicine
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949763467
Principal investigator 1 Eli Lilly and Company $1,002.00 09/27/2022 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 917840905
Principal investigator 1 ABBVIE INC. $936.00 07/27/2022 Non-covered Recipient Entity
ROPHE ADULT AND PEDIATRIC MEDICINE
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 889802423
Principal investigator 1 ABBVIE INC. $5,079.00 07/26/2022 Non-covered Recipient Entity
ROPHE ADULT AND PEDIATRIC MEDICINE
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 889802211
Principal investigator 1 Eli Lilly and Company $279,705.00 07/26/2022 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 917832069
Principal investigator 1 Eli Lilly and Company $3,776.00 07/06/2022 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS No dispute reported 06/30/2026 917832075
Recipient Eli Lilly and Company $55,234.00 06/30/2022 Covered Recipient Physician A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 917806599
Principal investigator 1 PFIZER INC. $17,110.00 06/22/2022 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 949811349
Principal investigator 1 ABBVIE INC. $1,592.00 06/07/2022 Non-covered Recipient Entity
ROPHE ADULT AND PEDIATRIC MEDICINE
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 889793855
Principal investigator 1 Eli Lilly and Company $18,556.00 06/03/2022 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 917834715
Principal investigator 1 ABBVIE INC. $6,078.00 05/04/2022 Non-covered Recipient Entity
ROPHE ADULT AND PEDIATRIC MEDICINE
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 889789523
Recipient Eli Lilly and Company $506.00 04/29/2022 Covered Recipient Physician EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) No dispute reported 06/30/2026 917806761
Principal investigator 1 Eli Lilly and Company $76,468.00 04/25/2022 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS No dispute reported 06/30/2026 917840169
Principal investigator 1 PFIZER INC. $17,110.00 04/19/2022 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 949701417
Principal investigator 1 Eli Lilly and Company $25,342.00 03/28/2022 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) No dispute reported 06/30/2026 917840163
Principal investigator 1 Eli Lilly and Company $132.00 03/28/2022 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) No dispute reported 06/30/2026 917842079
Principal investigator 1 PFIZER INC. $109.40 03/09/2022 Non-covered Recipient Entity
ROPHE ADULT AND PEDIATRIC
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 949810739
Principal investigator 1 Allergan, Inc. $1,463.15 03/08/2022 Non-covered Recipient Entity
BALANCED LIFE HEALTH CARE SOLUTIONS (DBA) SKY CL
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 864373347
Principal investigator 1 Allergan, Inc. $8,624.10 02/28/2022 Non-covered Recipient Entity
BALANCED LIFE HEALTH CARE SOLUTIONS (DBA) SKY CL
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 864371189
Principal investigator 1 PFIZER INC. $560.00 02/28/2022 Non-covered Recipient Entity
Rophe Adult and Ped Medicine
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 949810545
Principal investigator 1 Eli Lilly and Company $4,600.00 02/25/2022 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A PHASE 2, PARALLEL, COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 917839157
Principal investigator 1 PFIZER INC. $79.00 02/23/2022 Non-covered Recipient Entity
ROPHE ADULT AND PEDIATRIC
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 949810543
Principal investigator 1 PFIZER INC. $28.45 02/23/2022 Non-covered Recipient Entity
ROPHE ADULT AND PEDIATRIC
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 949810737
Principal investigator 1 PFIZER INC. $230.00 02/23/2022 Non-covered Recipient Entity
ROPHE ADULT AND PEDIATRIC
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 949810985
Principal investigator 1 PFIZER INC. $18,065.00 02/21/2022 Non-covered Recipient Entity
ROPHE ADULT AND PEDIATRI
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 949758557
Principal investigator 1 Allergan, Inc. $9,787.85 02/17/2022 Non-covered Recipient Entity
BALANCED LIFE HEALTH CARE SOLUTIONS (DBA) SKY CL
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 864369737
Recipient Eli Lilly and Company $36,536.00 02/08/2022 Covered Recipient Physician A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917809845
Principal investigator 1 Allergan, Inc. $7,543.00 01/12/2022 Non-covered Recipient Entity
BALANCED LIFE HEALTH CARE SOLUTIONS (DBA) SKY CL
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 864366665
Principal investigator 1 Eli Lilly and Company $6.00 01/11/2022 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A PHASE 2, PARALLEL, COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 917832053
Principal investigator 1 Eli Lilly and Company $7,862.00 01/04/2022 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) No dispute reported 06/30/2026 917834711
Principal investigator 1 Eli Lilly and Company $1,812,654.00 01/04/2022 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917839149
Principal investigator 1 Eli Lilly and Company $349,070.00 01/04/2022 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) No dispute reported 06/30/2026 917841077